We are live on ! Find out more
RPRX

Repros Therapeutics Inc.
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

Back to rankings

46 hedge funds and large institutions have $14.5M invested in Repros Therapeutics Inc. in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

923% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $150K

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

53% more capital invested

Capital invested by funds: $9.45M → $14.5M (+$5.05M)

7% more funds holding

Funds holding: 43 → 46 (+3)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

Holders
46
Holders Change
+3
Holders Change %
+6.98%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
10
Closed
5
Calls
$1.53M
Puts
$150K
Net Calls
+$1.39M
Net Calls Change
+$458K

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$1.71M
2
GAI
General American Investors
New York
+$623K
3
Renaissance Technologies
Renaissance Technologies
New York
+$208K
4
VKH
Virtu KCG Holdings
New York
+$51.4K
5
Wolverine Trading
Wolverine Trading
Illinois
+$37.5K

Top Sellers

Rank Fund Capital Flow
1
AIM
Alambic Investment Management
California
-$111K
2
BIM
Bogle Investment Management
Massachusetts
-$104K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$92.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$89.1K
5
ARTA
A.R.T. Advisors
New York
-$55K
Name Holding Trade Value Shares
Change 		Change in
Stake
MWAC
26
Mariner Wealth Advisors (Cincinnati)
Ohio
$23K – – –
CLOS
27
Compagnie Lombard Odier SCmA
Switzerland
$13K – – –
Wells Fargo
28
Wells Fargo
California
$11K – – –
Creative Planning
29
Creative Planning
Kansas
$10K – – –
BA
30
BlackRock Advisors
Delaware
$9K – – –
BIM
31
BlackRock Investment Management
Delaware
$8K -$1.12K -567 -13%
UBS Group
32
UBS Group
Switzerland
$7K +$7.12K +3,597 +4,282%
BFEC
33
Benjamin F. Edwards & Company
Missouri
$6K – – –
Deutsche Bank
34
Deutsche Bank
Germany
$5K -$4 -2 -0.1%
BWP
35
Baldwin Wealth Partners
Massachusetts
$4K – – –
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3K – – –
TRCT
37
Tower Research Capital (TRC)
New York
$3K +$2.98K +1,506 New
Bank of Montreal
38
Bank of Montreal
Ontario, Canada
$2K – – –
Citigroup
39
Citigroup
New York
$2K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$2K +$1.78K +900 New
KTC
41
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
KF
42
Krilogy Financial
Missouri
$1K – – –
AIM
43
Alambic Investment Management
California
– -$111K -69,191 Closed
ARTA
44
A.R.T. Advisors
New York
– -$55K -34,315 Closed
JP Morgan Chase
45
JP Morgan Chase
New York
– -$45K -27,750 Closed
Walleye Trading
46
Walleye Trading
New York
– -$1K -900 Closed
PNC Financial Services Group
47
PNC Financial Services Group
Pennsylvania
– +$346 +175 New
1
2

RPRX Hedge Fund Activity: Q3 2016 in Review

46 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q3 2016, worth a combined $14.5M — up 53% from $9.45M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new RPRX positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 10 trimmed.

The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.71M. The largest seller was Alambic Investment Management, exiting entirely with an estimated $111K sold.

  • 46 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q3 2016, up from 43 in Q2 2016.
  • Funds reported $14.5M of Repros Therapeutics Inc. stock for Q3 2016, up 53% quarter-over-quarter.
  • 8 funds opened new Repros Therapeutics Inc. positions in Q3 2016 and 5 closed out, a net change of +3 holders.
  • The largest Repros Therapeutics Inc. buyer in Q3 2016 was Sphera Funds Management, an estimated $1.71M added.
  • The largest Repros Therapeutics Inc. seller in Q3 2016 was Alambic Investment Management, an estimated $111K sold.

Based on aggregated 13F filings for Q3 2016.